United Therapeutics Co. (NASDAQ:UTHR) Position Increased by Focus Partners Wealth

Focus Partners Wealth raised its position in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 127.1% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 1,917 shares of the biotechnology company's stock after purchasing an additional 1,073 shares during the period. Focus Partners Wealth's holdings in United Therapeutics were worth $679,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Ensign Peak Advisors Inc increased its stake in shares of United Therapeutics by 1.7% in the 4th quarter. Ensign Peak Advisors Inc now owns 37,657 shares of the biotechnology company's stock worth $13,287,000 after acquiring an additional 640 shares during the last quarter. Ethic Inc. purchased a new position in shares of United Therapeutics in the 4th quarter valued at about $959,000. FORA Capital LLC purchased a new position in shares of United Therapeutics in the 4th quarter valued at about $1,895,000. Frontier Capital Management Co. LLC boosted its stake in shares of United Therapeutics by 36.0% in the 4th quarter. Frontier Capital Management Co. LLC now owns 243,681 shares of the biotechnology company's stock valued at $85,980,000 after buying an additional 64,527 shares during the period. Finally, Clark Capital Management Group Inc. boosted its stake in shares of United Therapeutics by 3.9% in the 4th quarter. Clark Capital Management Group Inc. now owns 189,341 shares of the biotechnology company's stock valued at $66,807,000 after buying an additional 7,053 shares during the period. Hedge funds and other institutional investors own 94.08% of the company's stock.

United Therapeutics Stock Performance

NASDAQ UTHR traded down $1.07 during trading hours on Friday, hitting $307.65. 269,594 shares of the company's stock were exchanged, compared to its average volume of 442,728. The business's 50 day moving average is $299.63 and its 200-day moving average is $337.46. United Therapeutics Co. has a 12-month low of $264.33 and a 12-month high of $417.82. The firm has a market capitalization of $13.88 billion, a P/E ratio of 13.51, a price-to-earnings-growth ratio of 0.97 and a beta of 0.58.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $6.29 by $0.34. The business had revenue of $794.40 million during the quarter, compared to analysts' expectations of $726.82 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The company's revenue for the quarter was up 17.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $6.17 EPS. As a group, equities research analysts anticipate that United Therapeutics Co. will post 24.48 EPS for the current fiscal year.

Insider Buying and Selling at United Therapeutics

In other news, COO Michael Benkowitz sold 10,000 shares of the stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $360.76, for a total value of $3,607,600.00. Following the completion of the sale, the chief operating officer now owns 2,577 shares in the company, valued at approximately $929,678.52. This trade represents a 79.51% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Paul A. Mahon sold 11,000 shares of the firm's stock in a transaction that occurred on Thursday, April 3rd. The shares were sold at an average price of $306.18, for a total value of $3,367,980.00. Following the sale, the executive vice president now owns 36,781 shares of the company's stock, valued at approximately $11,261,606.58. This trade represents a 23.02% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 55,500 shares of company stock valued at $17,054,780 over the last ninety days. Corporate insiders own 10.30% of the company's stock.

Analyst Ratings Changes

Several equities research analysts recently weighed in on UTHR shares. Morgan Stanley boosted their target price on United Therapeutics from $346.00 to $348.00 and gave the stock an "equal weight" rating in a research note on Thursday, May 1st. HC Wainwright restated a "buy" rating and set a $425.00 price target on shares of United Therapeutics in a research note on Monday, May 5th. Wells Fargo & Company restated an "equal weight" rating and set a $314.00 price target (down previously from $395.00) on shares of United Therapeutics in a research note on Friday, April 25th. Wall Street Zen lowered United Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Friday, May 2nd. Finally, Bank of America upgraded United Therapeutics from an "underperform" rating to a "neutral" rating and set a $314.00 target price on the stock in a research report on Monday, April 21st. Four equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat, United Therapeutics has an average rating of "Moderate Buy" and a consensus target price of $392.00.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.